Abstract: PLS antigens I and II are derived from the pili-like structures on the cell wall of Human type Streptococcus mutans of the serotypes c, e, f and g and the serotype d, respectively and capable of specifically inhibiting the adherence (infection) of the corresponding strains to the teeth of humans. These antigens are a kind of glycoprotein comprising protein (about 15-25%) and carbohydrates (about 75-85%) and have a molecular weight of about 60,000-90,000. It is possible to isolate these antigen by extracting the intact cells in a hypertonic buffer solution at a pH of 6-8 and at a temperature below the denaturing point of the antigenic protein and fractionating the resultant antigen from the extract thereby obtained. A non-cariogenic vaccine comprises as antigen PLS antigens I and/or II. Non-cariogenic antibodies may be obtained by immunizing a mammal with PLS antigens I and/or II to produce the corresponding antibodies in the body of the mammal and recovering the resultant antibodies from the mammal.

Abstract: Non-cariogenic composition, which comprises as active ingredient the living cells of a Human type strain of Streptococcus mutans capable of inhibiting the growth of cariogenic strains of S. mutans and incapable of inducing dental caries, in association with a carrier or excipient suitable for oral administration, said strains of S. mutans being isolated from the oral cavity of humans as naturally-occuring strains. The non-cariogenic composition may be administered orally in the form of liquid, semi-solid or solid compositions, preferably in the form of yogurts containing edible lactic acid-producing bacilli or in the form of a freeze-dried composition containing such edible lactic acid-producing bacilli. The non-cariogenic composition may prevent or at least inhibit human dental caries induced by cariogenic S. mutans and moreover effective against other cariogenic oral bacilli such as edible lactic acid-producing bacilli known per se.

Abstract: Disclosed are novel erythromycin derivatives, or salts thereof, represented by the following general formula: ##STR1## and processes for preparing the same. The erythromycin derivatives described above have an excellent effect of stimulating the gastrointestinal contractile motion and have low toxicity, and the preparations containing these compounds can be advantageously used as digestive tract contractile motion stimulants.

Abstract: Non-cariogenic composition, which comprises as active ingredient the living cells of a Human type strain of Streptococcus mutans capable of inhibiting the growth of cariogenic strains of S. mutans and incapable of inducing dental caries, in association with a carrier or excipient suitable for oral administration, said strains of S. mutans being isolated from the oral cavity of humans as naturally-ocuring strains. The non-cariogenic composition may be administered orally in the form of liquid, semi-solid or solid compositions, preferably in the form of yougurts containing edible lactic acid-producing bacilli or in the form of a freeze-dried composition containing such edible lactic acid-producing bacilli. The non-cariogenic composition may prevent or at least inhibit human dental caries induced by cariogenic S. mutans and moreover effective against other cariogenic oral bacilli such as edible lactic acid-producing bacilli known per se.

Abstract: Disclosed are digestive tract contractile motion stimulants containing compounds, or salts thereof, represented by the following general formula: ##STR1## The compounds described above have an excellent effect of stimulating the gastrointestinal contractile motion, and the preparation of the present invention containing these compounds can be advantageously used as digestive tract contractile motion stimulants.

Abstract: A growth promoting composition for animals containing an erythromycin derivative wherein a dimethylamino radical of the 3'-position is converted into a primary amino radical, a secondary amino radical, a tertiary amino radical other than the dimethyl amino radical, or a quaternary ammonio radical.This composition does not exhibit the antimicrobial activity at all or show the extremely decreased antimicrobial activity, and has the excellent effect to improve the feed efficiency of domestic animals.

Abstract: A vaccine, comprising as antigen, at least a part of the cell of strains of Streptococcus sanguis having a high pathogenic potential and capable of decomposing raffinose and mellibiose, in association with a pharmaceutically acceptable carrier or excipient. Preferably, the antigen is derived from the pili-like structures on the surface layer of the cells. Antibodies produced by immunizing a mammal with said antigen to produce the corresponding antibodies in the body of said mammal and recovering the resultant antibodies from the mammal. A pharmaceutical composition, comprising as active ingredient said antibodies, in association with a pharmaceutically acceptable carrier or excipient. Said vaccine, antibodies and antibody-containing composition may be used for treating human and animal diseases caused or aggravated by said microorganisms such as MCLS.

Abstract: A pharmaceutical composition for inducing contractile motility of the gastrointestinal tract in humans and animals, comprising as active ingredient 8,9-anhydroerythromycin 6,9-hemiketals, anhydroerythromycins, derivatives thereof and/or pharmaceutically acceptable salts thereof, in association with a pharmaceutically acceptable carrier or excipient. The active compounds may be produced by chemical modification of erythromycin and exhibit no or little antimicrobial activity. By administering the present composition to humans and animals, contractile motility of the gastrointestinal tract similar to the motility occurring naturally under normal conditions may be effectively induced.

Abstract: A vaccine for preventing or at least inhibiting periodontitis of humans and animals, which is induced or deteriorated by the action of oral microorganisms, which comprises an antigen isolated from the pili of an oral microorganism capable of inducing and/or deteriorating periodontitis and having the pili on the cell surface. For example, antigens isolated from the pili of Actinomyces viscosus, Actinomyces naeslundii, Actinobacillus actinomycem comitans, Bacteroides gingivalus and mutant strains thereof may be used solely or in combination for the preparation of the present vaccine. In one embodiment, the vaccine comprises an antigen isolated from the pili of Actinomyces viscosus which is a representative periodontitis-inducing oral microorganisms in association with one or more other antigens isolated from other virulent oral microorganisms.

Abstract: Antibiotic AM-3603 which is also designated as irumamycin is represented by the following formula: ##STR1## This substance is active upon certain Gram-positive bacteria, phytopathogenic fungi and dermatophytes, and is of interest in treating various diseases of humans and animals caused by infectious bacteria and fungi and also useful for agricultural purposes. Antibiotic AM-3603 may be prepared by fermentation, in which a microorganism capable of producing AM-3603 is cultured in a medium to accumulate AM-3603 in the cultured broths, from which AM-3603 is recovered. A preferred strain is Streptomyces sp. AM-3603 (FERM-P 5619; NRRL 12518).

Abstract: The present invention teaches a new antibiotic nanaomycin E represented by the formula: ##STR1## Nanaomycin E is active against Gram-positive bacteria, Trichophyton and Mycoplasma and may be used as antibacterial and therapeutic agents for humans and animals. Nanaomycin E is also a useful starting material for the preparation of nanaomycin A which latter nanaomycin has the highest activity among the various nanaomycin-type compounds. Nanaomycin E is produced by fermentation of a microorganism belonging to the genus Streptomyces and capable of producing nanaomycin E, especially Streptomyces rosa variant notoensis (FERM-P 2209; ATCC 31135) and recovering the same from the fermented liquor.

Abstract: The present invention teaches a new antibiotic nanaomycin E represented by the formula: ##STR1## Nanaomycin E is active against Gram-positive bacteria, Trichophyton and Mycoplasma and may be used as antibacterial and therapeutic agents for humans and animals. Nanaomycin E is also a useful starting maerial for the preparation of nanaomycin A which latter nanaomycin has the highest activity among the various nanaomycin-type compounds. Nanaomycin E is produced by fermentation of a microorganism belonging to the genus Streptomyces and capable of producing nanaomycin E, especially Streptomyces rosa variant notoensis (FERM-P 2209; ATCC 31135) and recovering the same from the fermented liquor.

Abstract: The present invention relates to new compound designated as nanaomycin B represented by general formula: ##STR1## Nanaomycin B is a quinone type and is active on mycoplasma, Gram-positive bacteria and trycophyton. This compound is useful as a medicament for infectious diseases of humans and animals caused by a parasite of trichophyton or mycoplasma etc. The acute toxicity (LD.sub.50, intra-penetrial injection) in mice of this compound is 169 mg/kg. Nanaomycin B is produced by fermentation in which a nanaomycin-producing strain belonging to the genus Streptomyces is cultured in a medium under aerobic conditions and the accumulated nanaomycin B in the cultured broths is recovered therefrom.